Nav: Home

Researchers turn to policy to tackle health disparities in an age of personalized medicine

August 08, 2016

BOSTON (August 8, 2016)--A new paper from researchers from Tufts University and colleagues addresses how increased support for minority-focused research, community-based participatory research, and studies of gene-environment interactions may improve science's understanding of chronic diseases across races and ethnicities. The paper, published today in Health Affairs, outlines policy efforts needed to ensure the advancement of genetic applications in healthcare in ways that reduce existing disparities.

Focusing on breast cancer and chronic kidney disease, the authors show that while genetic and molecular knowledge has grown and been used to fight these diseases in the last decade, significant racial and ethnic health disparities persist and hinder universal progress. The policy recommendations they propose are:
  • Increasing the enrollment of non-white participants in research on complex diseases.

  • Community-based participatory research to promote genetic literacy and encourage more volunteers to become involved in research.

  • Funding research on the interactions of genes and the environment.

  • Educating healthcare providers as well as patients about the risks, benefits and limitations of genetic research.

"We need to collect more data from groups for whom we currently have insufficient information so that we can improve care for all individuals. If we don't expand our efforts, the quality and effectiveness of genetic research and services will be limited in ways that can perpetuate health disparities. The Precision Medicine Initiative for one will be a big step forward in this endeavor and is to be commended for including community-based health provider organizations in its network to attract volunteers. Increasing diversity in research and testing will help maximize the possibilities of precision medicine," said senior author José M. Ordovás, Ph.D., director of the Nutrition and Genomics Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University.

The authors identify three key areas where their recommendations would make improvements: incomplete genetic databases, inadequate treatment options, and insufficiently understood disease mechanisms.

People with non-European ancestries are underrepresented in genetic databases, limiting the ability to apply genetic knowledge to reduce disease in these groups. While researchers know that hereditary breast cancer is linked to mutations in the BRCA1 or BRCA2 genes, the "normal" genetic sequence for these genes was determined based on women of European and Ashkenazi Jewish descent. Studies show that African-American and Hispanic women are much less likely than white women to receive genetic counseling or testing for hereditary breast cancer; the absence of this data perpetuates an incomplete genetic database on which clinical decisions about treating breast cancer rely.

For many diseases, clinical advances in treatment have developed based on new knowledge of genetic markers. Studies show that non-Hispanic black women tend to be diagnosed with more advanced sporadic breast cancer (occurring without family history) compared to white women. Many potential genetic markers might explain the racial and ethnic disparity in tumor aggressiveness in sporadic cancer. However, the small number of tumor samples from non-European women offers inadequate details about patient and tumor characteristics and restricts the use of genetic knowledge in clinical treatments for all individuals.

Similarly, treatments tailored to individuals with high-risk genotypes for certain diseases have not yet been identified because the molecular mechanisms behind the diseases are unknown as well. Researchers know that African-Americans are disproportionately affected by variants in the APOL1 gene which can increase a person's risk of kidney disease by up to seven times. Due to insufficient understanding of the molecular mechanisms by which the gene increases disease risk, effective treatments elude clinicians.

"Ultimately, we want the knowledge gained from a reduction in health disparities to lead to an increase in treatments for people who are most at risk. If we understand the aggressive breast cancer subtype that more frequently affects black women, we might be able to expand treatment options. We want to look at environmental factors as well as tumor biology to know how they contribute to the disease, and how we might then attack it," said first author Caren E. Smith, D.V.M., a scientist in the Nutrition and Genomics Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University.
-end-
Additional authors of this paper are Stephanie M. Fullerton, associate professor at the University of Washington, in Seattle; Keith A. Dookeran, assistant professor at the School of Public Health at the University of Illinois at Chicago and chair and CEO of the Cancer Foundation for Minority and Underserved Populations; Heather Hampel, professor at the Ohio State University Comprehensive Cancer Center in Columbus; Adrienne Tin, assistant scientist at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland; Nisa M. Maruthur, assistant professor at the Johns Hopkins University School of Medicine, the department of epidemiology at the Johns Hopkins Bloomberg School of Public Health, and the Welch Center for Prevention, Epidemiology, and Clinical Research at Johns Hopkins University; Jonathan C. Schisler, assistant professor at the University of North Carolina at Chapel Hill; Jeffrey A. Henderson, president and CEO of the Black Hills Center for American Indian Health in Rapid City, South Dakota; and Katherine L. Tucker, professor at the University of Massachusetts Lowell.

The authors of the paper were supported by the Centers for Population Health and Health Disparities grants from the National Cancer Institute and the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (award numbers P50CA148143, P50CA148596, P50HL105187, P50HL105185, P50CA105632, P50HL105189, P50HL105188, P50CA106743, P50HL105184, P50CA148110). In addition, Caren Smith was supported by the NHLBI (award number K08HL112845); Keith Dookeran by the Komen Foundation and the Cancer Foundation for Minority and Underserved Populations; and Adrienne Tin by the Renal Disease Epidemiology Training Program at the National Institute of Diabetes and Digestive and Kidney Diseases (award number T32DK007732).

Smith, C.E., Fullerton S.M., Dookeran K.A., Hampel H., Tin A., Maruthur N.M., Schisler J.C., Henderson .JA., Tucker K.L., and Ordovas J.M., "Using genetic technologies to reduce, rather than widen, health disparities," Health Affairs. 2016; 35(8):1367-1373. doi:10.1377/hlthaff.2015.1476

About the Jean Mayer USDA Human Nutrition Research Center on Aging and the Friedman School of Nutrition Science and Policy

For three decades, the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University has studied the relationship between good nutrition and good health in aging populations. Tufts research scientists work with federal agencies to establish the USDA Dietary Guidelines for Americans, the Dietary Reference Intakes, and other significant public policies. The Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts University is the only independent school of nutrition in the United States. The school's eight degree programs - which focus on questions relating to nutrition and chronic diseases, molecular nutrition, agriculture and sustainability, food security, humanitarian assistance, public health nutrition, and food policy and economics - are renowned for the application of scientific research to national and international policy.

Tufts University, Health Sciences Campus

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
One-third of breast cancer patients not getting appropriate breast imaging follow-up exam
An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren't receiving this follow-up exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
Low breast density worsens prognosis in breast cancer
Even though dense breast tissue is a risk factor for breast cancer, very low mammographic breast density is associated with a worse prognosis in breast cancer patients.
Is breast conserving therapy or mastectomy better for early breast cancer?
Young women with early breast cancer face a difficult choice about whether to opt for a mastectomy or breast conserving therapy (BCT).
Breast density and outcomes of supplemental breast cancer screening
In a study appearing in the April 26 issue of JAMA, Elizabeth A.
Full dose radiotherapy to whole breast may not be needed in early breast cancer
Five years after breast-conserving surgery, radiotherapy focused around the tumor bed is as good at preventing recurrence as irradiating the whole breast, with fewer side effects, researchers from the UK have found in the large IMPORT LOW trial.

Related Breast Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...